BridgeBio (BBIO) announced the Medicines and Healthcare products Regulatory Agency has granted marketing authorization in the United Kingdom for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Bayer (BAYRY) will be responsible for all commercial activity for acoramidis in the UK.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
- Buy Recommendation for BridgeBio Pharma Driven by Promising ATTR-CM Launch and Late-Stage Portfolio Potential
- BridgeBio price target raised to $53 from $49 at H.C. Wainwright
- BridgeBio management to meet with Piper Sandler
- BridgeBio reports pre-specified subgroup analysis of ATTRibute-CM trial